Month: June 2026

Introduction and Objective: Individuals with early stage T1D may engage in LC (e.g., carbohydrate restriction, vitamin use) to delay progression. Little is known about use of LC in individuals in DMT trials. We characterized LC reported in DMT trials conducted by TrialNet.Methods: We analyzed pooled participant questionnaires from 6 DMT trials for prevention (n=4) or […]

Introduction and Objective: The high cost of insulin hinders access and utilization of insulin, a life-sustaining medication, for U.S. adults with diabetes. By 2025, 27 states and DC have passed and implemented insulin out-of-pocket (OOP) caps, but the reach of these caps is uncertain. In this study, we estimate the population being protected by state […]

Introduction and Objective: Emerging adults (EAs) with type 1 diabetes (T1D) face elevated A1c levels and diabetes distress. Continuous glucose monitors (CGM) improve outcomes, but little is known about CGM breaks – particularly during this developmental period. Using mixed methods, we investigated the prevalence, drivers, behaviors during, and impacts of CGM breaks through surveys and […]

Introduction and Objective: CGM and GLP-1 receptor agonists (RA) are two distinct and increasingly used treatment strategies in T2D, each associated with meaningful improvements in clinical outcomes. However, there is little real-world evidence comparing their effectiveness in primary care or evaluating whether combined use offers added benefit in HbA1c and body weight (BW).Methods: We conducted […]

Introduction and Objective: Obesity is a serious health issue for Indigenous Americans residing in Arizona and genetic factors are believed to play a role in the development of this chronic disease. The aim of this study was to identify and mechanistically study variants that associate with BMI. We identified 3 variants associated with BMI located […]

Introduction and Objective: Survodutide, a dual glucagon/GLP-1 receptor agonist in phase 3 trials for obesity and metabolic dysfunction-associated steatohepatitis, contains a C18-diacid half-life extension (HLE) group for once weekly dosing. This study thoroughly investigated the in vitro receptor pharmacology of survodutide and the impact of its HLE using time-resolved cellular assays.Methods: GCGR and GLP-1R both […]

Introduction and Objective: GDM dietary therapy targets maternal glycemia in gestation but fails to address postpartum metabolic disease risk. In an RCT, pregnant women on a higher-complex CHO diet showed an improved OGTT response at 36 wks’. We studied the diets’ sustained effect 2 mos postpartum (PP).Methods: At diagnosis, women with diet-managed GDM were randomized […]

Introduction and Objective: The hallmark of T1D is the destruction of pancreatic insulin producing β-cells by autoreactive T cells. The quest for new antigen-specific autoreactive cells as well as for strategies that may target them are highly required to provide a more successful therapeutic option for T1D. Starting from many evidence suggesting a potential role […]

Introduction and Objective: Metformin is an increasingly common medication used in pregnancy. However, metformin crosses the placenta raising concerns about unintended long-term effects to offspring health. This study examined whether metformin exposure during early development alters skeletal muscle metabolism in juvenile offspring and increases the risk of insulin resistance and obesity.Methods: Adult female Rhesus macaques […]